Deutsche Bank’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-10,000
Closed -$15K 5363
2017
Q3
$15K Sell
10,000
-1,400
-12% -$1.71K ﹤0.01% 4607
2017
Q2
$14K Hold
11,400
﹤0.01% 4626
2017
Q1
$12K Hold
11,400
﹤0.01% 4595
2016
Q4
$11K Hold
11,400
﹤0.01% 4692
2016
Q3
$11K Hold
11,400
﹤0.01% 4659
2016
Q2
$16K Hold
11,400
﹤0.01% 4819
2016
Q1
$13K Hold
11,400
﹤0.01% 4766
2015
Q4
$13K Hold
11,400
﹤0.01% 4875
2015
Q3
$18K Hold
11,400
﹤0.01% 4814
2015
Q2
$23K Hold
11,400
﹤0.01% 4879
2015
Q1
$33K Sell
11,400
-147
-1% -$466 ﹤0.01% 4514
2014
Q4
$35K Buy
11,547
+10,000
+646% +$33.7K ﹤0.01% 5313
2014
Q3
$4K Hold
1,547
﹤0.01% 5595
2014
Q2
$3K Hold
1,547
﹤0.01% 5709
2014
Q1
$3K Hold
1,547
﹤0.01% 5322
2013
Q4
$3K Sell
1,547
-58,751
-97% -$165K ﹤0.01% 5153
2013
Q3
$484K Buy
60,298
+60,101
+30,508% +$463K ﹤0.01% 3519
2013
Q2
$1K Buy
+197
New +$1.43K ﹤0.01% 5329

Other funds holding CELGZ

Deutsche Bank's CELGZ Position: Q4 2017 in Review

Deutsche Bank sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q4 2017, closing a stake of 10,000 shares — an estimated $15K sold.

Deutsche Bank first reported a position in CELGZ in Q2 2013 and held it in 18 quarters. The position peaked at $484K in Q3 2013. 19 funds tracked by Wall St. Rank hold CELGZ as of Q4 2017.

  • Deutsche Bank reported no remaining Celgene Corporation Contingent Value Rights position as of Q4 2017 after selling out during the quarter.
  • Deutsche Bank sold 10,000 Celgene Corporation Contingent Value Rights shares in Q4 2017, an estimated $15K.
  • Deutsche Bank first reported a position in Celgene Corporation Contingent Value Rights in Q2 2013 and held it in 18 quarters.
  • Deutsche Bank's Celgene Corporation Contingent Value Rights position peaked at $484K in Q3 2013.
  • 19 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q4 2017.

Based on Deutsche Bank's 13F filing for Q4 2017, filed 14 Feb 2018.